Discontinuation report IMIPENEM AND CILASTATIN FOR INJECTION USP
| Report ID | 144467 |
| Drug Identification Number | 02358336 |
| Brand name | IMIPENEM AND CILASTATIN FOR INJECTION USP |
| Common or Proper name | IMIPENEM AND CILASTATIN FOR INJECTION USP |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | CILASTATIN IMIPENEM |
| Strength(s) | 250MG 250MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10PSOIJ CA |
| ATC code | J01DH |
| ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2021-08-20 |
| Remaining supply date | 2021-08-20 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4600 RUE ARMAND-FRAPPIER SAINT-HUBERT, QUEBEC CANADA J3Z 1G5 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2021-08-23 | French | Compare |
| v1 | 2021-08-23 | English | Compare |
Showing 1 to 2 of 2